Applied Therapeutics (APLT) Stock Price, News & Analysis

Company Overview

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapies for genetically defined diseases. Its research strategy centers on structure-based drug design and proprietary screening technologies aimed at correcting underlying metabolic dysfunction in disorders characterized by enzyme deficiencies and toxic metabolite accumulation.

The company’s lead investigational candidate, AT-007, is an aldose reductase inhibitor engineered to cross the blood–brain barrier and is currently in clinical development for classic galactosemia. In addition to AT-007, Applied Therapeutics is advancing multiple programs targeting rare neurological and endocrine disorders, leveraging its platform to identify and optimize compounds that address high unmet medical needs in orphan and genetically defined patient populations.

Founded and headquartered in New York City, Applied Therapeutics has established collaborative partnerships with academic research institutions and contract research organizations throughout North America and Europe to support its preclinical and clinical operations. The company is guided by a leadership team with extensive experience in drug discovery, clinical development and regulatory affairs, positioning Applied Therapeutics to advance its pipeline toward key clinical milestones and potential regulatory approval.

Key Stats

• Today's Range: $1.27 to $1.49
• 50-Day Range: $0.41 to $1.47
• 52-Week Range: $0.30 to $10.62
• Volume: 4.99 million shs
• Average Volume: 12.76 million shs
• Market Capitalization: $211.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.13
• Consensus Rating: Hold

Applied Therapeutics Stock Analysis - MarketRank™

Applied Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 235th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Applied Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Applied Therapeutics has a consensus price target of $4.13, representing about 180.6% upside from its current price of $1.47.

Amount of Analyst Coverage

Applied Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Applied Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Applied Therapeutics is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Applied Therapeutics is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Applied Therapeutics has a P/B Ratio of 3.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.83% of the outstanding shares of Applied Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Applied Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Applied Therapeutics has recently increased by 23.44%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Applied Therapeutics does not currently pay a dividend.

Dividend Growth

Applied Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.88

Percentage of Shares Shorted

7.83% of the outstanding shares of Applied Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Applied Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Applied Therapeutics has recently increased by 23.44%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.15

News Sentiment

Applied Therapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Applied Therapeutics this week, compared to 5 articles on an average week.

Search Interest

64 people have searched for APLT on MarketBeat in the last 30 days. This is an increase of 2,033% compared to the previous 30 days.

MarketBeat Follows

10 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Applied Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.60% of the stock of Applied Therapeutics is held by insiders.

Percentage Held by Institutions

98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

APLT Stock Analysis - Frequently Asked Questions

How have APLT shares performed this year?

Applied Therapeutics' stock was trading at $0.8562 at the beginning of 2025. Since then, APLT stock has increased by 71.7% and is now trading at $1.47.

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics Inc. (NASDAQ:APLT) announced its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.02.

When did Applied Therapeutics IPO?

Applied Therapeutics (APLT) raised $60 million in an initial public offering on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.

How do I buy shares of Applied Therapeutics?

Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/20/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:APLT
• CIK: 1697532
• Web: www.appliedtherapeutics.com
• Phone: (212) 220-9226
• Fax: N/A
• Employees: 30
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Applied Therapeutics: $4.13
• High Price Target: $8.00
• Low Price Target: $1.50
• Potential Upside/Downside: +180.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$105.62 million
• Net Margins: N/A
• Pretax Margin: -55,523.77%
• Return on Equity: -354.24%
• Return on Assets: -144.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.94
• Quick Ratio: 1.94

Sales & Book Value

• Annual Sales: $460 thousand
• Price / Sales: 460.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.49 per share
• Price / Book: 3.00

Miscellaneous

• Outstanding Shares: 144,010,000
• Free Float: 141,708,000
• Market Cap: $211.69 million
• Optionable: Optionable
• Beta: 2.07